We are onira research
At Onira Research, we dedicate our days to researching sleep ... and we spend our nights dreaming of improving the patient’s quality of life. Sleep is an extraordinary process, in which we have a lot to learn to develop new diagnostic and therapeutic solutions.
Onira Research first product
Hiparco was born from the project, HIPARCO-Score, started in 2012 at the University of Chicago. The researchers Dr. Manuel Sánchez and Dr. Ferrán Barbé, experts and international references in sleep research, found a match associating the sleep apnea treatments with patients affected by Resistant Hypertension
Their research allows the development of a patented in-vitro diagnostic kit that determines if a patient with Resistant Hypertension could be treated using a CPAP (Continuous Positive Air Pressure) device, originally indicated for the treatment of obstructive sleep apnea.
ONIRA has determined that, in around 70% of these patients, the application of this treatment lowers their blood pressure and they manage to stabilize and get out of the danger zone.
HIPARCO allows us to discriminate which patients can specifically benefit from this treatment, which could otherwise be counterproductive. It is a diagnostic technology that revolutionizes the treatment of one of the most afflicting disease worldwide.
1,3 billion hypertensive people in the world in 2018
+ 1.5B in 2025 and growing due to current lifestyle conditions
8 million deaths per year
Related to hypertension, according to WHO studies and data
130M people who do not improve with drugs
Medically known as Resistant Hypertensive
Hypertension in the world
Hypertension is a disease currently treated by drugs that allow the blood pressure of affected patients to be lowered. However, approximately 10% of all those affected do not respond to any medication.
Today there is no way to treat them, to lower their blood pressure. Doctors from all over the world and different specialties (nephrologists, internists, cardiologists) are trying drug after drug, without success.
These patients are considered Hypertensive Resistant..
According to data from the W.H.O. after 1 to 3 years without effective treatment, these 130M people will have a serious cardiological episode, including risk of death.
Our tech, in detail.
Hiparco, our in-vitro diagnostic test, predicts whether patients with resistant hypertension will be able to lower their blood pressure using positive air pressure (CPAP) treatment.
• Positive response with an average of 11 mmHg in blood pressure.
Higher than most hypotensive drugs!
• High reliability of results (AUC 0.92)
• Detailed results in a quantitative way (after software process)
Our technology is based on microRNAs profiles of expression from peripheral blood samples and its application in a software system that provides a score after passing through our algorithm (Hiparco-Score).
See our presentation video
Who we are
With studies in Business and Industrial Engineering, and executive Master from the I.E. Business School, he has an extensive professional career of + 17 years with various responsibilities in companies such as Google, Telefónica, PSA Peugeot-Citroen. Co-founder of several startups, lecturer and professor, he combines his passion for business development with teaching.
Management Team, CEO Founder
Dr. Manuel Sanchez
Doctor in Biology from the University of Lleida and Post-Doc from the University of Chicago. Author of +85 publications, he has received several awards for his research, such as that of the prestigious American Thoracic Society. Considered one of the promising young researchers in Europe, he is currently the national coordinator of the sleep research program in Spain, IRB Lleida principal researcher and professor at the University of Lleida.
Management Team, CSO Founder
Dr. Ferran Barbé
Doctor of Medicine from the Univ.Barcelona and Post-Doc from the Univ.Rene Descartes (Paris). Considered an international Key Opinion Leader in the field of respiratory and sleep research. With +280 publications, he has published in the prestigious international magazine NEMJ. He is currently clinical director at Arnau hospital, scientific director at CIBER, head of the research group at IRB and professor at the University of Lleida.
Board of advisors Founder
Graduated from Georgetown University and Master in Marketing from Siences Po Paris, + 20 years of experience in business development and innovation. Collaboration with +100 startups in multiple sectors, launch process & fundings. Regular advisor and non-executive director of multiple companies and foundations.
Board of advisors Founder
He has led numerous processes of business transformation, growth and internationalization in Spain, Europe, the USA and LATAM. Founder of several start-ups in the health sector, while helping other entrepreneurs to bring their business ideas to life and expand their reach globally.